AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1418054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 3882680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine once a day (in the morning)
Number of subjects: 0
Study 3882680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine twice a day (in the morning and at noon)
Number of subjects: 0
Study 3882680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (both regimens)
Number of subjects: 0
Study 31512923 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise video games (EVGs)
Number of subjects: 189
Study 31512923 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise (e.g., treadmill walking, stationary cycling)
Number of subjects: 189
Study 31512923 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (EVGs or standard exercise)
Number of subjects: 189
Study 30463809 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation of the right inferior frontal cortex (rIFC)
Number of subjects: 80
Study 30463809 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 80
Study 27490922 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 Fatty Acid Ethyl Esters (4 g/d)
Number of subjects: 0
Study 25131734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabin IPV (20:32:64 DU/dose)
Number of subjects: 60
Study 25131734 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted Sabin IPV (10:16:32 DU/dose)
Number of subjects: 60
Study 25131734 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Salk IPV (40:8:32 DU/dose)
Number of subjects: 60
Study 25131734 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccination groups
Number of subjects: 60
Study 22607857 — intervention group
Group type: COMPARATOR
Intervention: Canadian patients
Number of subjects: 2086
Study 19074536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/day)
Number of subjects: 438
Study 19074536 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (8-30 mg/day)
Number of subjects: 438
Study 19074536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 19074536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160 mg/day) during extension phase
Number of subjects: 438
Study 19074536 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (4-30 mg/day) during extension phase
Number of subjects: 438
Study 18400631 — intervention group
Group type: COMPARATOR
Intervention: Regular cigarette smoking
Number of subjects: 38
Study 18400631 — intervention group
Group type: COMPARATOR
Intervention: Mentholated cigarette smoking
Number of subjects: 38
Study 16036285 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous smoking reduction among past reducers
Number of subjects: 0
Study 16036285 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender and number of heart disease diagnoses
Number of subjects: 0
Study 16036285 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and history of chronic obstructive pulmonary disease
Number of subjects: 0
Study 16036285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine and nicotine levels per cigarette per day
Number of subjects: 0
Study 16036285 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous reduction
Number of subjects: 0
Study 16036285 — intervention group
Group type: EXPERIMENTAL
Intervention: Past history of heart disease
Number of subjects: 0
Study 16036285 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensation among past spontaneous reducers
Number of subjects: 0
Study 12448875 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious psychotherapy (RPT)
Number of subjects: 4
Study 12448875 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 4
Study 10510053 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (a platelet glycoprotein IIb/IIIa receptor antagonist)
Number of subjects: 853
Study 10510053 — intervention group
Group type: EXPERIMENTAL
Intervention: TnT-positive patients (TnT levels >0.1 microg/L)
Number of subjects: 853
Study 10510053 — intervention group
Group type: COMPARATOR
Intervention: TnT-negative patients (TnT levels ≤0.1 microg/L)
Number of subjects: 853
Study 10510053 — intervention group
Group type: EXPERIMENTAL
Intervention: TnT-positive patients
Number of subjects: 853
Study 7571666 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal interposition with pouch (JIP)
Number of subjects: 120
Study 7571666 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y pouch reconstruction (RYP)
Number of subjects: 120
Study 1827104 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg every 12 h
Number of subjects: 243
Study 1827104 — intervention group
Group type: COMPARATOR
Intervention: Penicillin VK 250 mg every 6 h
Number of subjects: 243
Study 7300705 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg a day)
Number of subjects: 24
Study 7300705 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 24
Study 30343264 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education program
Number of subjects: 110
Study 30343264 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic-based GDM education (Control)
Number of subjects: 110
Study 28219190 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided group (PCT group)
Number of subjects: 156
Study 28219190 — intervention group
Group type: COMPARATOR
Intervention: Regular antibiotic group (RAT group)
Number of subjects: 156
Study 25597563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower systolic blood pressure (SBP)
Number of subjects: 430
Study 25597563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower diastolic blood pressure (DBP)
Number of subjects: 430
Study 25597563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower mean arterial pressure (MAP)
Number of subjects: 430
Study 25597563 — intervention group
Group type: COMPARATOR
Intervention: Higher functional ability (control group)
Number of subjects: 430
Study 23744506 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombivax 2.5 µg
Number of subjects: 560
Study 23744506 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge dose of vaccine
Number of subjects: 560
Study 23744506 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose
Number of subjects: 560
Study 20400649 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with lidocaine and its metabolite (MEGX)
Number of subjects: 10
Study 20400649 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with bupivacaine enantiomers
Number of subjects: 10
Study 20400649 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with lidocaine and its metabolite (MEGX) and bupivacaine enantiomers
Number of subjects: 10
Study 19263132 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin adhesives
Number of subjects: 404
Study 19263132 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 404
Study 17166593 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the left DLPFC
Number of subjects: 26
Study 17166593 — intervention group
Group type: COMPARATOR
Intervention: Anodal occipital tDCS
Number of subjects: 26
Study 17166593 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 26
Study 15709453 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA AQ (triamcinolone acetonide), 220 microg, once daily for 3 weeks
Number of subjects: 295
Study 15709453 — intervention group
Group type: EXPERIMENTAL
Intervention: FP (fluticasone propionate), 200 microg, once daily for 3 weeks
Number of subjects: 295
Study 11182836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 914
Study 11182836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release dexfenfluramine
Number of subjects: 914
Study 11182836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 914
Study 9702146 — intervention group
Group type: EXPERIMENTAL
Intervention: Community policies to reduce youth access to tobacco (intervention communities)
Number of subjects: 14
Study 9702146 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 14
Study 8287743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouchitis patients (Group 2)
Number of subjects: 78
Study 8287743 — intervention group
Group type: COMPARATOR
Intervention: Normal pouch patients (Group 1)
Number of subjects: 78
Study 2978997 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 7.5 mg three times daily
Number of subjects: 36
Study 2978997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31327184 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day concomitant therapy (CT)
Number of subjects: 1141
Study 31327184 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (ST)
Number of subjects: 1141
Study 31327184 — intervention group
Group type: COMPARATOR
Intervention: 7-day clarithromycin-containing triple therapy (TT)
Number of subjects: 1141
Study 30672218 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group (acupuncture + five-element music therapy)
Number of subjects: 120
Study 30672218 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA) group
Number of subjects: 120
Study 30672218 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 120
Study 30672218 — intervention group
Group type: COMPARATOR
Intervention: Five-element music therapy group
Number of subjects: 120
Study 27448223 — intervention group
Group type: EXPERIMENTAL
Intervention: UPD plus adjunct aPDT
Number of subjects: 20
Study 27448223 — intervention group
Group type: COMPARATOR
Intervention: UPD only
Number of subjects: 20
Study 24835009 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc treatment at home (10-day course)
Number of subjects: 440
Study 24835009 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS) at home
Number of subjects: 440
Study 24835009 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc treatment at home
Number of subjects: 440
Study 24835009 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS use
Number of subjects: 440
Study 22676245 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-108 40 mg/day
Number of subjects: 97
Study 22676245 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-108 80 mg/day
Number of subjects: 97
Study 22676245 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-108 120 mg/day
Number of subjects: 97
Study 20100026 — intervention group
Group type: EXPERIMENTAL
Intervention: 340 mg oral magnesium (170 mg twice a day) for 6.5 months
Number of subjects: 55
Study 18714904 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening for intimate partner violence (IPV) using a standard set of questions during home visits.
Number of subjects: 6
Study 18714904 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth assessment of the family for mothers' exposure to IPV as part of the Healthy Babies Healthy Children program.
Number of subjects: 6
Study 15743278 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher homocysteine levels
Number of subjects: 1140
Study 15743278 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in homocysteine levels from the 25th to the 75th percentile
Number of subjects: 1140
Study 15743278 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects in the highest quartile of homocysteine levels
Number of subjects: 1140
Study 11487039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWH) in fixed doses
Number of subjects: 0
Study 11487039 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH in high prophylactic doses
Number of subjects: 0
Study 11487039 — intervention group
Group type: COMPARATOR
Intervention: LMWH and UFH
Number of subjects: 0
Study 11487039 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin in high prophylactic doses
Number of subjects: 0
Study 11487039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasaccharide
Number of subjects: 0
Study 9431632 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician intervention (notification of risk and recommendations for care)
Number of subjects: 268
Study 9431632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physician intervention)
Number of subjects: 268
Study 8500297 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term oral digoxin
Number of subjects: 34
Study 8500297 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 34
Study 3805752 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene D4 (LTD4) at doses of 3.1‐200 pmol
Number of subjects: 0
Study 3805752 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0
Study 3805752 — intervention group
Group type: COMPARATOR
Intervention: H1 and H2 antagonists
Number of subjects: 0
Study 3805752 — intervention group
Group type: COMPARATOR
Intervention: Local nerve block
Number of subjects: 0
Study 3805752 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene D4 (LTD4) at doses of 0.2‐200 pmol
Number of subjects: 0
Study 3805752 — intervention group
Group type: COMPARATOR
Intervention: Occlusion of vasculature to the test arm before injection of LTD4
Number of subjects: 0
Study 3805752 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent injections of LTD4
Number of subjects: 0
Study 3805752 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene D4 (LTD4) injections
Number of subjects: 0
Study 2524387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of ipratropium bromide
Number of subjects: 10
Study 2524387 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of ipratropium bromide (20 mg)
Number of subjects: 10
Study 2524387 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of ipratropium bromide
Number of subjects: 10
Study 31619483 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 30
Study 27861703 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight discordance >75th percentile
Number of subjects: 1688
Study 27861703 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight discordance >90th percentile
Number of subjects: 1688
Study 27861703 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight discordance
Number of subjects: 1688
Study 25667159 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-thumb-encircling hands technique
Number of subjects: 27
Study 25667159 — intervention group
Group type: COMPARATOR
Intervention: 2-finger technique
Number of subjects: 27
Study 23525929 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated weaning
Number of subjects: 92
Study 23525929 — intervention group
Group type: COMPARATOR
Intervention: Protocolized weaning
Number of subjects: 92
Study 21646062 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) for ISR
Number of subjects: 872
Study 21646062 — intervention group
Group type: COMPARATOR
Intervention: De novo lesions
Number of subjects: 872
Study 19181826 — intervention group
Group type: EXPERIMENTAL
Intervention: TIP (paclitaxel 175 mg/m(2) + cisplatin 75 mg/m(2) + ifosfamide 5 g/m(2))
Number of subjects: 154
Study 19181826 — intervention group
Group type: COMPARATOR
Intervention: TP (paclitaxel 175 mg/m(2) + cisplatin 75 mg/m(2))
Number of subjects: 154
Study 19181826 — intervention group
Group type: EXPERIMENTAL
Intervention: TIP
Number of subjects: 154
Study 19181826 — intervention group
Group type: COMPARATOR
Intervention: TP
Number of subjects: 154
Study 16434666 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine 8 g/day for 16 weeks
Number of subjects: 64
Study 16434666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 15117853 — intervention group
Group type: EXPERIMENTAL
Intervention: ST2 levels measured in serum
Number of subjects: 810
Study 15117853 — intervention group
Group type: EXPERIMENTAL
Intervention: ST2 quartiles analysis
Number of subjects: 810
Study 15117853 — intervention group
Group type: EXPERIMENTAL
Intervention: ST2 levels at 12 hours post-infarction
Number of subjects: 810
Study 15117853 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis controlling for clinical factors
Number of subjects: 810
Study 15117853 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital ST2 levels
Number of subjects: 810
Study 11697020 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (n = 50)
Number of subjects: 101
Study 11697020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 51)
Number of subjects: 101
Study 9231950 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-minute nap
Number of subjects: 33
Study 9231950 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute nap
Number of subjects: 33
Study 9231950 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-minute nap (sleep-deprived subjects)
Number of subjects: 33
Study 9231950 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-minute nap (narcoleptic patients)
Number of subjects: 33
Study 9231950 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute nap (narcoleptic patients)
Number of subjects: 33
Study 9231950 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute nap (sleep-deprived subjects)
Number of subjects: 33
Study 7705096 — intervention group
Group type: EXPERIMENTAL
Intervention: CVR releasing 30 mcg of ethinyl estradiol and 650 mcg of norethindrone acetate (30/650)
Number of subjects: 69
Study 7705096 — intervention group
Group type: EXPERIMENTAL
Intervention: CVR releasing 20 mcg of ethinyl estradiol and 1000 mcg of norethindrone acetate (20/1000)
Number of subjects: 69
Study 7705096 — intervention group
Group type: EXPERIMENTAL
Intervention: CVR releasing 25 mcg of ethinyl estradiol and 650 mcg of norethindrone acetate (25/650)
Number of subjects: 69
Study 7705096 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive containing norethindrone acetate/ethinyl estradiol
Number of subjects: 69
Study 3556264 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol/codeine
Number of subjects: 85
Study 3556264 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol/dextropropoxyphene
Number of subjects: 85
Study 31486133 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial laser therapy (Nd‐YAG laser) performed under sonographic control
Number of subjects: 12
Study 31486133 — intervention group
Group type: EXPERIMENTAL
Intervention: No procedure related complications
Number of subjects: 12
Study 28389158 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin (insulin glargine)
Number of subjects: 2931
Study 28389158 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin (insulin lispro mixture)
Number of subjects: 2931
Study 28389158 — intervention group
Group type: COMPARATOR
Intervention: No hypoglycemia
Number of subjects: 2931
Study 28389158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypoglycemia rate/month
Number of subjects: 2931
Study 25469720 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-mg iron pills
Number of subjects: 692
Study 25469720 — intervention group
Group type: EXPERIMENTAL
Intervention: 38-mg iron pills
Number of subjects: 692
Study 25469720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692
Study 25469720 — intervention group
Group type: COMPARATOR
Intervention: Educational group (letters thanking for donation)
Number of subjects: 692
Study 25469720 — intervention group
Group type: COMPARATOR
Intervention: Educational group (suggesting iron supplements or delayed donation)
Number of subjects: 692
Study 24190680 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase sleep condition
Number of subjects: 37
Study 24190680 — intervention group
Group type: COMPARATOR
Intervention: Decrease sleep condition
Number of subjects: 37
Study 22018294 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1443
Study 22018294 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1443
Study 18837797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysglycaemia in primary normoglycaemic ESRD patients on MHD
Number of subjects: 239
Study 18837797 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes diagnosis in dysglycaemia patients
Number of subjects: 239
Study 18837797 — intervention group
Group type: COMPARATOR
Intervention: Comparison with matched control MHD patients
Number of subjects: 239
Study 18837797 — intervention group
Group type: EXPERIMENTAL
Intervention: Increment in HbA1c
Number of subjects: 239
Study 18837797 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival in dysglycaemia patients
Number of subjects: 239
Study 17158426 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral cyanocobalamin (1000 microg/d) for 3 months
Number of subjects: 149
Study 17158426 — intervention group
Group type: COMPARATOR
Intervention: Normal MMA group with 0 microg cyanocobalamin/d
Number of subjects: 149
Study 17158426 — intervention group
Group type: COMPARATOR
Intervention: Normal MMA group with 25 microg cyanocobalamin/d
Number of subjects: 149
Study 17158426 — intervention group
Group type: COMPARATOR
Intervention: Normal MMA group with 100 microg cyanocobalamin/d
Number of subjects: 149
Study 12914120 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg i.v. every 8 hours
Number of subjects: 468
Study 12914120 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin 500 mg i.v. every 8 hours
Number of subjects: 468
Study 12914120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g i.v. every 12 hours plus metronidazol 500 mg twice daily
Number of subjects: 468
Study 12914120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone/sulbactam 2 g daily administered every 12 hours
Number of subjects: 468
Study 12914120 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone/sulbactam
Number of subjects: 468
Study 12914120 — intervention group
Group type: COMPARATOR
Intervention: Cefepime plus metronidazol
Number of subjects: 468
Study 12914120 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 468
Study 12914120 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 468
Study 12914120 — intervention group
Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 468
Study 11920167 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous factor V Leiden women
Number of subjects: 64